In any case, our study identified a new regulator of the HIF1α signaling pathway, RBCK1, which can modulate tumor progression in ER-positive breast cancer cells by modulating this pathway, providing a new target for the treatment of ER-positive breast cancer. This evidence concerns the gene HIF1A and neoplasm.